UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

~~MAY~~JUNE 1926, 2026

Date of report (Date of earliest event reported)

Bausch Health Companies Inc.

(Exact name of registrant as specified in its charter)

British Columbia

Canada

001-14956

98-0448205

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

2150 St. Elzéar Blvd. West, Laval, Québec, Canada H7L 4A8

(Address of Principal Executive Offices) (Zip Code)

(514) 744-6792

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, No Par Value	BHC	New York Stock Exchange	Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.~~07.~~02 ~~Submission~~Departure of ~~Matters~~Directors toor aCertain ~~Vote~~Officers; Election of ~~Security~~Directors; ~~Holders.~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On ~~May~~June 1926, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) ~~held its Annual Meeting~~ of ~~Shareholders~~his ~~(the~~decision ~~“Annual~~to ~~Meeting”).~~resign Atfrom the ~~Annual~~Board ~~Meeting, the shareholders~~ of ~~the~~Directors ~~Company voted on~~ (the ~~following three proposals~~“Board”), ~~each~~effective ofJune ~~which~~30, is2026, ~~described~~ in ~~detail~~connection inwith ~~the~~his ~~Company’s~~appointment ~~Management~~as ~~Proxy~~President ~~Circular~~ and ~~Proxy~~Chief ~~Statement.~~Executive ~~The~~Officer ~~results~~ of ~~each~~Knoa ~~matter~~Pharma ~~voted~~LLC. ~~upon are as follows:~~

~~Proposal No~~Mr. 1:Goettler’s ~~Election~~resignation ofwas ~~Directors.~~not ~~The~~the ~~shareholders~~result ~~elected~~of ~~the~~any ~~following~~disagreement ~~individuals~~with to the Company’s ~~Board~~on ofany ~~Directors,~~matter ~~including~~relating ~~Eiry W. Roberts, M.D., who was elected as a new director,~~ to ~~serve until~~ the ~~close of the~~ Company’s ~~2027 Annual Meeting of Shareholders~~operations, ~~until~~policies ~~their successors are duly elected~~ or ~~appointed,~~practices. ~~or until such director’s earlier resignation or removal:~~

Name	For	Withheld	Broker Non-Votes
Thomas J. Appio	196,814,621	2,743,810	79,859,606
Christian A. Garcia	196,711,908	2,846,523	79,859,606
Michael Goettler	196,757,828	2,800,603	79,859,606
Sarah B. Kavanagh	188,459,870	11,098,561	79,859,606
Frank D. Lee	183,885,617	15,672,814	79,859,606
Sandra Leung	195,931,772	3,626,659	79,859,606
John A. Paulson	196,214,806	3,343,625	79,859,606
Robert N. Power	186,236,066	13,322,365	79,859,606
Eiry W. Roberts, M.D.	196,972,752	2,585,679	79,859,606
Amy B. Wechsler, M.D.	195,813,955	3,744,476	79,859,606

Item 7.01 Regulation FD Disclosure

~~Proposal~~A ~~No.~~copy 2:of ~~Advisory~~the ~~Vote~~press onrelease, ~~Executive~~dated ~~Compensation.~~July ~~The shareholders approved~~1, ~~on a non-binding advisory basis~~2026, ~~the~~announcing ~~compensation~~Mr. ~~of the Company~~Goettler’s ~~Named~~resignation ~~Executive~~is ~~Officers~~furnished as ~~disclosed~~Exhibit in99.1 ~~the~~to ~~Compensation~~this ~~Discussion~~Current ~~and~~Report ~~Analysis~~on ~~section,~~Form ~~executive~~8-K ~~compensation tables~~ and ~~accompanying~~is ~~narrative~~incorporated ~~discussions~~herein ~~contained~~by ~~in the Management Proxy Circular and Proxy Statement~~reference.

For						Against						Abstain						Broker Non-Votes
189,432,400						9,588,417						537,614						79,859,605

The information in the preceding paragraph, as well as Exhibit 99.1 hereto, is being “furnished” pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any Company filing, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing and regardless of any general incorporation language in such filing.

~~Proposal~~Item No9.01 3:Financial ~~Appointment~~Statements of the Independent Registered Public Accounting Firm. The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2027 Annual Meeting of Shareholders and ~~authorized the Company’s Board of Directors to fix the auditors’ remuneration.~~Exhibits

For						Withheld
Exhibit No.						Description
276,774,936						2,643,100
99.1						Press release of the Company dated July 1, 2026
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Date~~BAUSCH HEALTH COMPANIES INC. By: ~~May~~/s/ 19Seana Carson Name: Seana Carson Title: Executive Vice President, ~~2026~~General Counsel

~~BAUSCH HEALTH COMPANIES INC. By~~Date: ~~/s/~~July ~~Seana Carson Seana Carson Executive Vice President~~1, ~~General Counsel~~2026

Filing Compare · Bausch Health Companies Inc.